The FDA has approved a supplemental new drug application for Valtrex (valacyclovir HCI) manufactured by GlaxoSmithKline.
Secukinumab Demonstrates Promise for Patients With Severe Hidradenitis Suppurativa Who Found Adalimumab Intolerable
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment
FDA Issues Alert on Counterfeit Botox: What Dermatology Clinicians Need to Know
ReV Up Your Vitiligo Treatment Strategies
Reviewing the Rosacea Pipeline: A Look at the Last 10 Years
Is Your Texting as Caring as Your Bedside Manner?